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Aging is accompanied by remodeling of the immune system. With time, this leads to
a decline in immune efficacy, resulting in increased vulnerability to infectious diseases,
diminished responses to vaccination, and a susceptibility to age-related inflammatory
diseases. An age-associated immune alteration, extensively reported in previous studies,
is the reduction in the number of peripheral blood naïve cells, with a relative increase in
the frequency of memory cells. These two alterations, together with inflamm-aging, are
considered the hallmarks of immunosenescence. Because aging is a plastic process,
it is influenced by both nutritional and pharmacological interventions. Therefore, the
role of nutrition and of immunomodulation in immunosenescence is discussed, due to
the multifactorial influence on these hallmarks. The close connection between nutrition,
intake of bioactive nutrients and supplements, immune function, and inflammation
demonstrate the key role of dietary strategies as regulators of immune response and
inflammatory status, hence as possible modulators of the rate of immunosenescence. In
addition, potential options for therapeutic intervention are clarified. In particular, the use
of interleukin-7 as growth factor for naïve T cells, the function of checkpoint inhibitors
in improving T cell responses during aging and, the potential of drugs that inhibit
mitogen-activated protein kinases and their interaction with nutrient signaling pathways
are discussed. Finally, it is suggested that the inclusion of appropriate combinations of
toll-like receptor agonists may enhance the efficacy of vaccination in older adults.
Keywords: aging, immunosenescence, immunomodulation, immunotherapy, nutrition
INTRODUCTION
People worldwide are living longer. In 2025, there will be about 1.2 billion people over the age
of 60, increasing to 2 billion by 2050 (1). However, the increase in lifespan does not coincide
with the increase in healthspan, i.e., the period of life free from serious chronic diseases and
disability. In fact, the influence of aging on humans is responsible for physiological dysfunctions
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in the different tissues, organs, and systems, including the
immune system (2, 3). The age-related involvement of immune
system leads to a progressive reduction in the ability to trigger
effective antibody and cellular responses against infections and
vaccinations. This phenomenon, called immunosenescence, a
term coined by Roy Walford, is multifactorial, and affects
both natural and acquired immunity, although T lymphocytes
are dramatically affected (4). In fact, aging process more
extensively affects acquired immunity than innate immunity
(3, 5). Several factors, such as genetics, nutrition, exercise,
previous exposure to microorganisms, biological and cultural
sex, and human cytomegalovirus (HCMV) status can influence
immunosenescence (3, 6–11).
Concerning sex, steroid hormones, linking to specific
receptors, differentially modulate the immune system. In general,
while estrogens increase the immune response, progesterone
and androgens have immune suppressive actions. However, a
few studies have analyzed the post-menopausal immune system
(12). Therefore, it is unclear whether age-related changes in the
immune system are different between men and women, although
some data show that immunosenescence develops earlier in men
than in women. This has been related to longer life expectancy
of women (8, 13, 14). In addition, no evidence exists that
males and females respond differently to therapeutic intervention
against immunosenescence.
Many studies have emphasized the importance of viruses,
such as herpes viruses, responsible for both latent and chronic
infections, in shaping T cell compartments during aging (15).
In particular, HCMV seropositivity seems related to many
functional T cell changes. HCMV status has a greater impact
than age on the immune system, because the virus contributes
to shape the immune profile and function during normal human
aging (16–18).
Understanding mechanisms of age-related disorders in
immune regulation is important to identify more efficient
strategies for immune rejuvenation and for effective induction
of vaccination-mediated immunity in older individuals. Aging
is a malleable process, affected by both nutritional and
pharmacological interventions (19, 20). Therefore, immune
system might also be prone to intervention. However, all
possible therapies aimed at non-specifically “rejuvenating” the
immune systemmight be counterproductive. In fact, the different
parameters observed between young and older people could also
be a product of the adaption vs. the exposome, i.e., all the stimuli
that the immune system has undergone during life. Therefore,
a targeted intervention for safe “rejuvenation” of the immune
status in older people should be necessary (21).
Within the past years, numerous studies of underlying
mechanisms of age-related immune decline have laid the
groundwork for the identification of targeted approaches (5,
22–24). We will discuss below the most relevant strategies
currently being investigated. We will also considered the role
of nutrition in immunosenescence and in its counteraction in
the section on dietary strategies currently being investigated.
Further, we will examine the available data on growth factors
[i.e., on interleukin (IL)-7], on monoclonal antibodies (MoAbs)
that affect immune checkpoints, and on drugs that inhibit
mitogen-activated protein kinases (MAPK) and their interaction
with nutrient signaling pathways. These treatments, representing
a promising therapeutic approach, will be treated in the section
on clinical approaches. In the section on the other approaches
in development, we will suggest that the inclusion of appropriate
combinations of toll-like receptor (TLRs) agonists might enhance
the efficacy of vaccination-mediated immunity in older adults.
Finally, at the end of conclusion, we will outline possible
future approaches.
SUMMARY OF IMMUNOSENESCENCE
Innate Immunity
The general picture of innate immunity in older people, which
emerges from several studies, is that of the down-regulation of
some functions and the up-regulation of others. We will discuss
data on dendritic cells (DCs) due to their relevance for the
immunotherapeutic approaches, including vaccination. For the
other aspects of innate immunity in older individuals, see (3, 25,
26). Briefly, natural killer (NK) cell cytotoxicity is well-preserved
in centenarians, and an increase in the actual number of NK
cells is observed in healthy aging. Neutrophils show reduced
function in bacteria phagocytosis and in the oxidative burst while
macrophages show reduced chemotaxis and phagocytosis, and
decreased cytokine production.
DCs, the most potent antigen presenting cells (APCs), can
be divided into three subsets according to the expression
of various markers (CD123, CD1c, CD141), one subset of
plasmacytoid DCs (pDCs) and two subsets of myeloid DCs
(mDCs) (27). Both pDCs and mDCs express TLRs that recognize
conserved pathogen-associated molecular patterns (PAMPs) on
microbes, and are key regulators of antimicrobial host defense
responses. The type of TLR-activatedDC determines the cytokine
pattern (28).
There are discordant data on age-related changes in the
frequency and absolute number of pDCs and mDCs. Regarding
the ability to secrete cytokines upon stimulation, there are
apparent inconsistencies in the available data for mDCs from
older population. pDCs are instead characterized by a marked
impairment of cytokine release in older people (27, 29).
Recognition of microbial components by TLRs culminates in the
secretion of type I interferons (IFNs) and cytokines that facilitate
the coordination of innate to acquired immune responses.
Peripheral blood mononuclear cells (PBMCs) isolated from
older individuals (≥65 years) exhibited a delayed and altered
response to stimulation with TLR agonists compared with cells
obtained from young adults (≤40 years). This delayed response
to agonists results in the reduced production of cytokines and
chemokines (29). On the other hand, the addition of PAMPs
to a subunit vaccine, triggering their corresponding pattern-
recognition receptors (e.g., TLRs) improves vaccine efficacy in
older humans and mice (25, 30–32). Accordingly, DCs together
with naïve T cells represent the most restrictive elements for the
immune response to primary viral infections in older people (33).
As the expression of TLRs remains constant during life,
defects in signal transduction should be responsible for this
impairment, as discussed by (24).
Frontiers in Immunology | www.frontiersin.org 2 September 2019 | Volume 10 | Article 2247
Aiello et al. Immunosenescence and Therapeutic Intervention
Acquired Immunity and the Hallmarks of
Immunosenescence
The quality and quantity of the T and B cell responses change
with increasing age, with consequent changes on the effectiveness
of the immune response. This leads to an inadequate immune
response against newly encountered antigens. The apparently
inevitable consequence of this complex scenario is the reduced
ability of older individuals to respond to novel antigens and
to vaccines, resulting in an increased susceptibility to infection
and in the development of age-related diseases, including
cancer (3). As critically reviewed by (3, 6, 16), a number
of longitudinal studies of octogenarians and non-agenarians
performed in Sweden defined an immunological risk phenotype
(IRP). Participants with the reversal of CD4/CD 8 T-cell ratio, a
reduced proliferative response to mitogenic stimuli, and severe
reduced B cells number showed reduced survival. Subsequently,
the data were implemented and related to HCMV seropositivity,
because HCMV seropositivity is closely related to the reversal
of CD4/CD 8 T-cell ratio. In fact, as discussed below, persistent
HCMV infection leads to chronic stimulation of CD8T cells,
which expand clonally showing an effector memory phenotype
characterized by low CD28 expression. The IRP was present in
around 15% of 85-years-olds in these studies at baseline. Follow-
up of 2-, 4-, and 6-years mortality revealed significantly higher
all-cause mortality in the IRP group than in the majority of other
octogenarians and non-agenarians. However, this IRP was not
confirmed in the Leiden 85-Plus study, a prospective population-
based cohort study of individuals at the age of 85 years living in
Leiden (NL). Thus, immune parameters associated with survival
may vary in diverse populations at different ages (6). Therefore,
we focus on the changes we have considered the hallmarks of
immunosenescence, based on the literature data (6, 23).
The hallmarks of immunosenescence include: (i) a reduced
ability to respond to new antigens; (ii) the accumulation of
memory T cells; (iii) a lingering level of low-grade inflammation
termed “inflamm-aging.” Mechanistically, immunosenescence is
only partially explained by organismal and cellular senescence.
Therefore, these hallmarks of immunosenescence would be
markedly affected by the history of the individual exposure to
pathogens (6, 23).
The reduced ability to respond to new antigens is linked to
a decreased number of peripheral naïve T and B cells (see last
paragraph of this section). Naïve T cells are abundant in youth
but may become “used up” by exposures to microorganisms over
the course of life, hence differentiating into memory lymphocyte
subsets. In addition, their number decreases following the
involution of primary lymphoid organs, because age-related
defects have been observed in their stroma. Some changes occur
early in the developmental progression from hematopoietic stem
cells (3). Thymus involution occurs at the time of puberty, and
is characterized by atrophy and replacement by adipose tissue.
This process seems related to the increase of sex hormones
and to the decrease of IL-7, a hematopoietic growth factor
secreted by stromal cells in the bone marrow and thymus. IL-7
exerts its action through the binding to a heterodimeric receptor
composed of an α chain (IL-7Rα or CD127) and the common
cytokine receptor γ chain (γc or CD132). CD127 is expressed on
lymphoid lineage cells at different stages of development, whereas
CD132 is shared with other cytokine receptors and expressed on
most hematopoietic cells (34, 35). Irrespective of thymic activity,
the naïve compartment only moderately decreases in size during
the following life decades, while mostly maintaining overall
diversity and distribution of clonal sizes. An abrupt contraction
is seen in later life. Therefore, at the age of 50, T cell production
is <10% of its previous peak levels. From an evolutionary
point of view, this occurs because exposure to new pathogens is
maximal during the first years of life, but less likely in later life
when immune memory for previously encountered pathogens
is both more prevalent and more significantly important for
survival (3, 22, 36).
The life-long chronic antigen load causes the filling of the
immunological space by a population of T lymphocytes with
a late-differentiated phenotype and the shrinkage of the T
cell repertoire. As previously stated, an age-related decrease in
absolute number of peripheral blood naïve T cells is consistently
found in all studies and in different human populations (22, 37).
Due to the lifelong and chronic exposure to pathogens, T cells
replicate several times and become late-differentiated effector
memory T cells with features of replicative senescence (38).
T cell senescence focuses on the phenotypic characteristics of
individual lymphocytes and refers mainly to a low proliferative
activity (39). Aging per se leads only to a relative accumulation
of memory cell subsets, linked to the decrease in naïve cell
populations. The absolute increase in memory T cells, called
memory inflation, is observed only in older people infected by
HCMV (40). These T cells do not express the co-stimulatory
molecule CD28, required for the activation of T cells. The
loss of CD28 occurs following cell proliferation, according
to the observation that the CD28− T cells have shorter
telomeres than CD28+ cells. These CD28− cells express high
levels of the adhesion molecule integrin CD11a/CD18 and
have high levels of perforin and granzyme, responsible for
the killing of the target cells. CD28 seems a good biomarker
of immunosenescence, as further suggested by findings that
late-differentiated CD8+/CD28− T cells tend to accumulate
particularly in older people, frail or affected by age-related
diseases. These cells display a highly differentiated phenotype,
expressing CD27, another co-stimulatory molecule, but not
CD28 (however, in CD28+ subset, CD28−CD27− seem to be
more frequent). They also carry short telomeres, lack telomerase
and express negative signaling receptors, such as programmed
cell death protein (PD)-1, which is involved in the down-
regulation of the immune system (see paragraph on checkpoints
inhibitors; the example of PD-1 and CTLA-4). Senescent T cells
also express CD57 displaying a high cytotoxic potential, and
killer cell lectin-like receptor subfamily G member 1. Late-stage
memory senescent T-cells may also acquire new functions, such
as suppressive activity, as demonstrated in vitro. In addition,
they are producers of pro-inflammatory cytokines (17, 18, 41–
47). However, a longitudinal study of 249 research participants
followed for 10 years has strongly suggested that HCMV infection
is not a primary causative factor in the age-related increase
in systemic inflammation (48). Therefore, the accumulation of
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memory T cells, especially late-stage differentiated CD8+ cells is
viewed as the result of depletion of the reservoir of naïve cells over
time by contact with pathogens and their conversion to memory
cells. However, the memory responses can be unsustained,
because T cell memory established in humans during early age
can deteriorate during the second half of life. The most obvious
example of unsustained memory responses is the reactivation
of latent varicella zoster virus (VZV) infection that manifests as
herpes zoster. A steady decline of VZV-specific CD4+ T cells over
time has been documented, which is only very transiently boosted
with zoster vaccination or reactivation (49). In contrast, high
frequencies of antigen-specific T cells reactive to HCMV persist
throughout life. T cell clones specific for HCMV dominate the
repertoire in the older people and contribute to the contraction
in diversity in the memory compartment (23).
Nearly 20 years ago, Looney et al. reported the dramatic
impact of HCMV on the immune system of older people (50).
This observation was subsequently described in numerous other
studies (18, 46). In the latent state, the intermittent production
of viral antigens prevents contraction of virus-specific T cells.
Therefore, the virus is responsible for the generation of a large
population of HCMV-specific CD8+ T cells, with a significant
increase in highly differentiated CD8+ effector memory T cells,
which expand clonally showing an effector memory phenotype
characterized by low CD28 expression. As previously stated, this
determines the phenomenon of memory cell inflation, leading
to the emergence of vast populations of resting effector CD8+
and, to a lesser extent, CD4+ cells. In older people, one or
a few clonal populations can occupy more than 25% of the
entire CD8+ cell pool (46, 51). These inflated HCMV-specific
memory T cells maintain their efficient effector functions for the
lifetime of the individual (40, 46, 52). Inflationary CD8+ cells,
after proper activation stimuli, can divide, secrete cytokines, and
execute cytolysis, i.e., they are not exhausted. However, there may
be a slight loss of control of HCMV replication in older compared
with younger people. In fact, HCMV load in blood markedly
increases in healthy people over the age of 70 years (53). Immune
changes associated with HCMV may have significant impact
during co-infection and vaccination, as well as on general and
immunological fitness. However, the correlation between HCMV
positivity and impaired responses is controversial because this
relationship is observed in some but not all studies (54–56).
Persistent antigenic challenges lead to a poor response to
newly encountered microbial antigens, as well as to a shift in the
immune system toward an inflammatory, autoimmune, T helper
(Th) 2 profile. In addition, the long-term chronic microbial
burden induces progressive activation of macrophages, hence
contributing to the chronic state of low-grade inflammation,
inflamm-aging, another hallmark of immunosenescence (3, 9,
57). This term defines the systemic state of chronic low-grade
inflammation considered a central biological pillar of the aging
process and a common pathogenetic mechanism of age-related
diseases, as well as a worse prognostic factor for all causes of
death (9, 57–59). In the course of aging, there is a reduction in the
ability to endure consequences of antigenic, chemical, physical,
and nutritional triggers of inflammation. Chronic and low-grade
inflammation can lead to tissue dysfunction and degeneration.
Our immune system is quite efficient in fighting acute infections
in young people, but not particularly efficient in responding
to chronic stimuli, especially when they occur late in life. This
leads to an increased production of pro-inflammatory cytokines
and acute phase proteins (59, 60). Oxidative stress also plays
an important role in determining and maintaining this low-
grade inflammation, which, in turn contributes to oxidative
stress (61, 62). Inflamm-aging results from the activation of
signaling networks critical to inflammation, such as those
regulated by the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) transcription factor, particularly when
combined with a variety of stimuli, such as senescent cells,
obesity, circulating mitochondrial DNA, gut microbiota and diet
triggering and sustaining inflammatory conditions (58, 63–68).
However, as previously stated, immunosenescence represents
the most important contributor to inflamm-aging, in turn,
contributing to impaired immune responses. In fact, inflamm-
aging is responsible for a high expression of micro (mi)-RNAs
that interfere with B cell activation, driving tumor necrosis
factor (TNF)-α production and inhibiting B cell activation as
measured in vitro (69). Increased serum levels of TNF-α are
also linked to a defective T cell response, in part due to
reduced expression of CD28 (21). Accordingly, in monocytes,
the pre-vaccination expression of genes related to inflammation
and innate immune response is negatively correlated to
vaccination-induced activation of influenza-specific antibody
responses (70).
Age-related B cell changes are similar to those observed in T
cell compartment and the effects on humoral immune response
are detrimental as well. Age also affects B cell numbers and B
cell repertoire diversity, as well as immunoglobulin isotypes and
receptor repertoire with a decrease in specific humoral immune
responses against new extracellular pathogens (71). Activated B
cells isolated from older adults display a reduced induction of
E47, a class I basic helix-loop-helix protein encoded by the E2A
gene. This is the key transcription factor, for the induction of
activation-induced cytidine deaminase (AID), involved in class
switching and somatic hypermutation. The reduced expression of
E2A might be responsible for the decreased avidity of antibodies
and diminished antibody-mediated protection (72, 73). This
defect might be linked to a reduced interaction with CD40L+
T helper cells, because, in older adults, the memory/effector T
cells show a reduced expression of CD40L, necessary for B cells
cooperation (74). The reduced levels of E47 and AID mRNA in
B cells from older individuals are also due to the reduced mRNA
stability. It is due to the higher expression of the inflammatory
mi-RNAs 16 and 155, which bind to the 3’-untranslated region of
E47 and AID mRNA, respectively, inducing mRNA degradation
(69). In addition to the decrease in circulating B lymphocytes,
there is a shift from immunoglobulin produced by naïve cells
(IgD, IgM) to immunoglobulin produced by memory B cells
(IgG, IgA). This is accompanied by an impaired ability to produce
high affinity protective antibodies against infectious agents and
the shrinkage of the repertoire diversity. The reduced serum
levels of IgM and IgD suggest a shift in the balance from the naïve
(CD27) toward the memory compartment (CD27+), although
this is not observed in all studies (71, 75–77).
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See Figure 1 for the schematic changes occurring
during aging.
DIETARY STRATEGIES CURRENTLY BEING
INVESTIGATED
There is a mutual interaction between nutrition, intake of
particular bioactive dietary components, immune function,
and inflammatory status, hence a close relation with the
hallmarks of immunosenescence (78, 79). Many existing data
demonstrate the key role of foods as regulators of immune
response and inflammatory status, hence as possible modulators
of the rate of immunosenescence, particularly inflamm-aging
(11, 80). Other data have demonstrated the importance of
following a specific, even personally tailored, dietary pattern
(81). However, the intricate cellular and molecular network of
immune system makes difficult to identify targeted strategies
to rejuvenate specific compartment of immunity. Starting from
supplementation with a single nutrient, leading to the application
of experimental dietary pattern, much progress has been made
in this field. The main barrier to better clarity remains the wide
heterogeneity among human beings, linked to different life-style
and genetic factors that influence the rate of immunosenescence
(6, 10, 11, 82). Data discussed below show that the main
target of dietary strategies is inflamm-aging, because diet,
biotics, and nutraceuticals can show anti-inflammatory and anti-
oxidant properties.
Diet
The high rate of long living people and the low incidence of
cardiovascular disease in many Mediterranean countries suggest
the importance of a diet rich in fruits, vegetables, whole grains,
legumes, and olive oil (probably the main anti-aging food in
this area). The reduced consumption of animal proteins, in
particular red and cured meat, is also important. The efficacy
of this diet results as an attenuation of inflammation and
oxidative stress, and from the maintenance of a condition of
eubiosis of the microbiota, involved in the general improvement
of immune response in these populations (68, 83–86). In
particular, the Mediterranean diet down-regulates the levels of
inflammatory mediators, such as soluble intercellular adhesion
molecule (ICAM)-1, vascular cell adhesion molecule (VCAM-1),
FIGURE 1 | Schematic changes occur during aging. The immunosenescence in older people is characterized by thymic involution, altered T and B cell responses,
altered naïve/memory ratio, increased serum levels of IgG and IgA, a chronic low grade inflammation, and a poor response to newly encountered microbial antigens,
including vaccines. The reduced ability to respond to new antigens, the accumulation of memory T cells and the lingering level of low-grade inflammation
“inflamm-aging”) are considered hallmarks of immunosenescence. See the text for the acronyms. increase; decrease.
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C reactive protein, and IL-6, as well as many other biomarkers of
inflammation (87–90).
A new interesting approach related to the possible reversion
of immunosenescence is caloric restriction. NF-κB, mechanistic
target of rapamycin (mTOR), and MAPK, pathways closely
related to aging and inflammation are modulated by caloric
restriction that downregulates the activation of IL-1β, IL-6,
and tumor necrosis factor (TNF)-α genes, hence the pro-
inflammatory state (20, 91, 92). More specifically, the results
obtained by administration of different cycles of fasting,
mimicking diet or long-term fasting influences inflamm-aging
(20). These dietary patterns explicate their activity, particularly,
during the refeeding period, reducing the rate of aging because
of their antioxidant and anti-inflammatory effects, and possibly
counteracting some other aspects of immunosenescence. The
hypothetical explanation might be the disposal of damaged cells
with growth of new functional cells.
Minor effects on immune function, after a brief starvation
period of 72 hours, were seen in ten healthy, normal-weight,
young volunteers. They showed an increase in suppressor cell
numbers but no change in the number of peripheral blood
leucocytes or in the differential counts (93). Unfortunately,
these studies are severely limited by their complexity, further
confounded by the small number of cases analyzed and the poor
participants compliance (81).
New insights may also come from the use of caloric
restriction mimetics, such as metformin, an activator of 5
′
AMP-activated protein kinase (AMPK). It is a drug, typically
administrated in type 2 diabetes but proposed as an anti-
aging molecule for humans, such as the study called “Targeting
Aging with Metformin” (94). Metformin can trigger AMPK,
a pathway activated by energy depletion, i.e., by low levels
of intracellular adenosine triphosphate (ATP), leading to the
extension of healthy lifespan in model organisms (95). In
mice with collagen-induced arthritis, metformin administration
had an anti-inflammatory effect on arthritis due to the
inhibition of Th17 cell differentiation, a subset of pro-
inflammatory cells producing IL-17, and the upregulation of T
regulatory cells (Tregs) differentiation along with the suppression
of osteoclast differentiation (96, 97). Contrarily to caloric
restriction, undernutrition, which is common in older people, is
associated with an immunocompromised state, linked to altered
T cell numbers, a reduced response to antigens, impaired release
ofmediators, such as cytokines, and decreased phagocytosis and
NK cell activity. This makes older people enable to trigger an
efficient immune response to newly encountered pathogens. In
such conditions of poor nutrition, the use of supplements, such as
zinc, copper, iron, vitamins, nutraceuticals, and probiotics could
be desirable and more appropriate than caloric restriction, as
demonstrated by previous studies (98, 99).
Micronutrients
Nutritional status is crucial for the health status of older
adults. Changes in phenotypic features, mainly loss of teeth
and alterations in taste receptors, and gut disorders as well,
determine a variation in both quality and quantity of food
intake, contributing to general alterations in metabolism (100).
Many studies have examined the influence of micronutrients
and their influence on the enhancement of immune function in
older adults (11, 79, 101, 102). Micronutrients, such as vitamins
and minerals, are essential for the efficient performance of the
immune system. They are needed in trace quantities, because the
homeodynamic range is small, but the maintenance of a correct
amount and balance is very rare in older people (often even
in adults and young), both for scarcity and for excess due to
unnecessary supplementation (78, 103).
One of the main micronutrients related to physiologic
processes associated with immune system, and one of the
main studied factors, is zinc. It is involved in many molecular
processes, such as signal transduction, apoptosis, proliferation,
and differentiation of cellular components of the immune
system. Even slight deficiencies in zinc can have important
consequences (104–107). Zinc deficiency can cause decreased
levels of serum thymulin, a zinc dependent peptide hormone
produced by thymic epithelial cells, with an activity that is
progressively reduced with age, with a peak in pre-adolescence
(78, 104, 108). The active form of thymulin induces the
expression of markers of T lymphocyte activation, promoting
T-mediated functions, acting both on the early and on the
late phases of lymphocyte differentiation (109, 110). As shown
in a randomized, doubleblind, placebo-controlled trial, after
zinc supplementation for 12 months (45mg elemental Zn
gluconate/day), the incidence of infections was significantly
lower, plasma zinc was significantly higher, and generation of
TNF-α and oxidative stress markers was significantly lower
in the zinc-supplemented participants than in the placebo
group (both groups composed of 55–87 years old persons).
Another doubleblind, randomized, controlled trial performed
with zinc supplementation in old people (25mg as zinc sulfate,
once a day for 3 months, mean age of placebo group 80.6
± 7.8, mean age of supplemented participants 79.5 ± 6.8)
demonstrated increased levels of activated T helper and cytotoxic
T lymphocytes, with a higher relative percentage of T cells with
respect to the total circulating lymphocytes in zinc-supplemented
older adults (105, 106, 111). Given the dose-dependent effect
of zinc, both as a pro- and anti-oxidant, its presence in the
normal range is essential for regulating the levels of reactive
oxygen species (112). These studies highlight the importance
of the zinc for immune function, but contrasting results exist,
possibly reflecting the intrinsic complexities of this type of
investigation (11).
Vitamin supplementation studies in older adults have
demonstrated a role for vitamin E in the production of IL-2 as
well as the activation induced T cell proliferation in naïve but
not in memory T cells (78, 113–115). However, this response
is variable, depending on genetics and immune functionality
(102). Moreover, age-related oxidative stress, hence inflamm-
aging, can be counteracted by vitamin C supplementation. In
addition, it seems that this vitamin is involved in enhanced
antibody generation and in differentiation and maturation of
immature T-cells as well as of NK cells. Because vitamin C
is water-soluble and humans have low storage capacity, its
regular intake is up to 100-fold higher than that for many other
vitamins (116, 117).
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Probiotics, Prebiotics, and Symbiotics
The use of probiotics, prebiotics and symbiotics, i.e., the
combination of pro and prebiotics, as immunomodulators,
which act on microbiota, is very common. However, no
strong cause-effect relation often exists between their use and
specific end-points. Gut microbiota that plays an active part
in healthy status, is compromised in older adults due to
malnutrition, use of medications and immunosenescence itself.
Therefore, the administration of specific strains of Lactobacilli
and Bifidobacteria as probiotics as well as fructooligosaccharides,
galactooligosaccharides, and other prebiotics, or the combination
of both might constitute a benefit for immunocompromised
people (118–122).
Data from supplementation studies with pro- or prebiotics
in older adults show a control of inflammatory status because
their use is responsible for a lower production of TNF-α,
IL-1β, and IL-6 as well as an increase of anti-inflammatory
cytokine IL-10, by PBMCs. In addition, these biotics improve
the innate immune responses by the modulation of phagocytosis
and cytotoxicity against specific bacteria, such as Staphylococcus
aureus, increase activity of peripheral blood NK cells, and lower
CD25 expression by resting T lymphocytes (123). However, the
complexity of randomized controlled trials and lack of specific
biomarkers in humans make difficult the reproducibility of
the data (124). Moreover, healthy status, including absence of
disease and nutritional status, seems to be crucial for their
action as demonstrated by null results on immunomodulation
after administration of prebiotics in older adults vaccinated with
influenza or pneumococcal vaccines (125). Further studies are
summarized in a very recent review by Suez et al., although
in this case too, it is highlighted the weakness of the existing
data (124). Therefore, a strong limitation linked to the study
of these potential modulators is the lack of mechanistic studies
that could reveal the molecular mechanisms underlying their
action. This would allow a targeted and effective use, and would
reduce the bias linked to individual variability and the conflicting
existing results present in literature. Although meta-analyses and
systematic reviews report interesting data, they cannot replace
multicenter, randomized controlled clinical trials to address the
relevance of the use of probiotics or the composition of the
microbiota, both accompanied by molecular explanation of the
observed evidence.
Nutraceuticals
Recently, various bioactive food components associated with
health-related effects have been called nutraceuticals. These food
compounds, mainly found in plant-based foods and fatty fish,
have been implicated in offering physiological health benefits
over and above basic nutritional requirements (126–128). Now,
there is much interest in optimizing the immune response,
and in reducing inflammation in older adults by increasing the
intake of certain bioactive food agents (129, 130). Many studies
have investigated how immune function and inflammation are
directly affected by nutraceuticals. They provide evidence that
increasing intake of some of them above the habitual and
recommended dose levels can enhance some aspects of immune
function, and reduce the level of inflammatory status, increasing
cellular resistance to aging (131–133). Below, we examine the
immunomodulatory effects of three classes of nutraceuticals,
namely carotenoids, polyphenols, and polyunsaturated fatty acids
(PUFAs), summarizing the most relevant nutritional studies
on the reciprocal interactions between these dietary agents
and immunosenescence.
Carotenoids are naturally occurring pigments found in most
fruits and vegetables. They primarily exert antioxidant, hence
anti-inflammatory, effects, but individual carotenoids may also
act through other mechanisms, including immune-enhancing
activities (134, 135). Jyonouchi et al. observed that lutein and
astaxanthin increased the ex vivo antibody response of mouse
splenocytes to T-cell antigens (136). Older adults supplemented
with carotenoids (30mg β-carotene, 15mg lycopene and 9mg
lutein) had a shift to T cells expressing a mature phenotype
and, in addition, higher IgA serum levels, and an increase in
NK cells (137). Watson et al. report that higher doses of β-
carotene (30 and 60 mg/day; instead of 15, 30, and 45) increase
T helper cells and NK cells number (138). Although higher doses
of carotenoids are not easily achievable in the diet of population,
these findings suggest that low doses are insufficient to affect
immune responses. Enhanced NK cell cytotoxicity was observed
in participants treated with oral β-carotene and, similarly, long-
term β-carotene supplementation increased NK cell activity in
older adults (139, 140).
Dietary polyphenols are the biggest group of phytochemicals
and they are defined as bioactive non-nutrient plant compounds.
They are in fruits, vegetables, grains, and other plant foods,
the consumption of which has been linked to reduction in risk
of major age-related diseases (141, 142). In fact, as discussed
below, their main action is the control of inflammation.
Consumption of cocoa polyphenols rich in flavonoids (40
g/day) with 500ml of skimmed milk, by participants at high
cardiovascular disease risk (≥55 years), significantly reduced
the expression of cell adhesion molecule very late antigen-
4, CD40, and CD36 on monocytes. This treatment also
lowered circulating levels of the inflammatory markers P-
selectin and ICAM-1, compared with monocytes from the
control group (only skimmed milk) (143). In vitro studies
have shown that administration of olive oil polyphenols (caffeic
acid and oleuropein glycoside) to human whole blood cultures
stimulated with lipopolysaccharides significantly reduced IL-1β
levels compared with stimulated control cultures that were not
incubated with olive oil polyphenols. Interestingly, responses
were inversely correlated to the dose (144). A small scale
(n = 23) pilot study has shown that daily consumption of
12 green olives, containing oleuropein and hydroxytyrosol,
significantly reduced serum IL-6 and malondialdehyde (a lipid
peroxidation marker) levels after 30 days of consumption by
healthy adults (90). Although several reviews have postulated
potential beneficial effects of polyphenols on the immune
response of older adults, there have been limited studies on
this topic (145). However, the major effects of polyphenols
are associated with increased release of IL-2 and IFN-
γ, hence enhancing immune response (146). For example,
resveratrol, a polyphenol typically found in red wine, grape
skins, and berries, induces a significant increase in T helper
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cells and in the delayed-type hypersensitivity response of aged
rats (147).
In addition to carotenoids and polyphenols, several studies
have also shown that dietary lipids can modulate the immune
response. Fatty acids that have this role include the long-chain
PUFAs of the omega-3 (n-3) and omega-6 (n-6) classes. n-6
PUFAs, derived from plants and land animals, have minimal
effects on immune response. n-3 PUFAs, eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA), found mainly in fish
and fish products and in some plants (flax seeds), have the
most significant impact on immune cells. These have anti-
inflammatory properties inhibiting the formation of eicosanoids
and synthesis of pro-inflammatory cytokines (IL-1β, TNF-α,
IL-6), chemokines (IL-8, monocyte chemoattractant protein 1),
and adhesion molecules (ICAM-1, VCAM-1, selectins) (148).
However, because dose, timing of administration, and participant
age are important modulating factors of the effect of these
molecules, contrasting results exist and only few studies focus on
their use in older adults (149–154).
CLINICAL APPROACHES CURRENTLY
BEING INVESTIGATED
Growth Factors
The various aspects of IL-7 physiology raise the possibility that
reduction of this pleiotropic cytokine level could contribute to
the age-related decrease in the absolute number of thymocytes
and naïve T cells. Therefore, IL-7 might be used as a therapeutic
agent to enhance thymopoiesis in lymphopenic patients or
in older individuals, so counteracting the first hallmark of
immunosenescence, i.e., the reduction of naïve T cells. In fact,
the profound structural remodeling that characterizes the thymic
involution also affects thymic epithelial cells with a consequent
reduction in the intrathymic production of IL-7 (155, 156).
IL-7 produced by thymic epithelial cells provides survival and
proliferative signals to immature double negative CD4−CD8−
thymocytes and promotes V(D)J recombination of the T cell
receptor (TCR) γ-c locus (157). Mutations in the IL-7Rα or γc in
humans lead to severe combined immunodeficiency, confirming
the importance of the IL-7 signaling pathway in the development
of T cells (158, 159). At later stages, the IL-7/receptor signaling
complex is required for the homeostatic proliferation of naïve T
cells in the periphery, exerting a higher effect in the cytotoxic T
cell subsets. The high expression of IL-7Rα on naïve T cells allows
the maintenance of the pool of these cells, but there are limited
amounts of IL-7 under physiological conditions. Following the
encounter with its cognate antigen, naïve T cells lose IL-7Rα
expression and differentiate into effector T cells. IL-7R down-
regulation guarantees an efficient use of the limited amount of
IL-7 to naïve T cells that need it, driving their proliferation and
preserving their phenotype (160). IL-7Rα is re-expressed at the
memory stage, ensuring cell survival and proliferation inmemory
T cell pool too (156).
Interestingly, IL-7Rα chain is an integral component of
the receptor for thymic stromal lymphopoietin (TSLP). TSLP
provides normally a co-mitogenic activity that is less potent than
that of IL-7 (161). However, to best of our knowledge no study
has been performed on the possible role of TSLP in the treatment
of immunosenescence.
In the first clinical trial in humans, patients with metastatic
cancer (age range 20–59 years) treated with different doses
of IL-7 showed a dose-dependent increase in circulating
CD4+ and CD8+ lymphocytes along with a decrease in Tregs
(162). Since then, numerous other clinical trials have used
the administration of IL 7 for treating patients with various
malignancies and chronic viral infections. In HIV-infected
patients, with persistently low CD4+ T-cell counts despite viral
suppression, repeated cycles of recombinant human IL-7 induced
a dose-dependent increase in circulating levels of both naïve and
memory CD4+ and mostly naïve CD8+ T cells (163).
Therefore, some data suggest that IL-7 could have a
therapeutic potential in improving the clinical outcome
in settings that require enhanced immunological
responses. However, in the complex scenario of aging, the
immunorestorative properties of IL-7 may not be as great as
initially hoped, most probably due to the deterioration of the
thymus structure. The integrity of cortical and medullary thymic
architecture and the presence of functional thymic epithelial
cells are required to support and maintain thymopoiesis (164).
Therefore, IL-7 effect on T cell development probably should
require the preceding restoration of the thymic architecture.
Checkpoint Inhibitors; The Example of
PD-1 and CTLA-4
The role of the immune checkpoint inhibitors, MoAbs that
inhibit the expression of certain proteins made by T cells and
some cancer cells, or antibodies that block the activation of
inhibitory receptors, are pivotal for the management of cancer
that occurs both in young and old patients. In fact, immune
checkpoint inhibitors promote the immunological control of
cancer cells by blocking the immune inhibitory responses that
are evolutionary designed to prevent continuing immunological
responses once an antigenic stimulus has been eradicated (165).
However, there is a gap in the knowledge of the role of immune
checkpoint inhibitors in the control of immune response in older
patients because the data from randomized clinical trials are
conflicting and often lack adequate statistical power.
The PD-1 and the cytotoxic T-lymphocyte antigen (CTLA)-
4 are examples of checkpoint inhibitory receptors. The first
regulates the inhibition and the fine-tuning of T cell responses.
The second is a protein that contributes to the suppressor
function of Tregs, mediating the inhibitory effect through the
coordinated actions with the co-stimulatory receptor CD28.
Activation of CD28 induces on lymphocytes and monocytes the
expression of PD-1, which in turn interacts with its ligand (PD-
L1) to regulate the balance between stimulatory and inhibitory
signals needed for effective immune responses against antigens.
This engagement leads to the inhibition of CD28− mediated co-
stimulation, hence of TCR-mediated lymphocyte proliferation
and cytokine secretion. The modulation of these pathways boosts
anti-cancer immunity. Interestingly, the expression of PD-1
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increases on T cells of older adults and its blockade partially
restores T cells to functional competence (166–168).
The studies we discuss below are clinical studies based
on the response to cancer. However, positive clinical data
mean an increase in effector cell immune response, i.e., that
therapy is in some ways targeting immunosenescence, or at
least, dealing with the consequences of immunosenescence. In
fact, immunosenescence influences the efficacy of the immune
checkpoint inhibitors in older people (169); accordingly, the
therapy is less efficient in patients≥75 years (see below), probably
due to a greater degree of immunosenescence. Consequently,
there is limited evidence of successful therapy with immune
checkpoint inhibitors in older adults, although a few observations
of effectiveness in some patients are very encouraging. In
the metastatic melanoma, for example, the use of the MoAb
Nivolumab, a PD-1 inhibitor, alone or in combination with other
antagonists, has survival benefits independently on age (170,
171). In another study, the administration of PD-L1 antibody
Atezolizumab also shows positive results for all participants
enrolled (172). In these studies, T cells of older adults were still
able to respond to the blockade of their inhibitory receptors
with a recovery of cytotoxic activity. Moreover, there is evidence
about the efficacy of anti PD-1/PD-L1 MoAbs in older patients
with non-small cell lung cancer (NSCLC) compared with
chemotherapy. The benefit of immunotherapy in terms of
response is stackable between younger and older patients (173).
Regarding the CTLA-4 use, several preclinical and clinical
trials have reported the role of CTLA-4 inhibition in some
kinds of cancer. In particular, the blockade with Ipilimumab can
establish an anti-leukemic effect after allogeneic hematopoietic
stem cell transplantation and can restore anti-tumor reactivity
for patients with relapse (174). Although durable responses
were observed, the efficacy of CTLA-4 inhibition needs to
be confirmed. However, a recent meta-analysis analyzed the
contextual administration of anti-CTLA-4 (tremelimumab and
ipilimumab) and anti-PD-1 (nivolumab and pembrolizumab)
molecules in four different settings: melanoma, prostate cancer,
renal cell carcinoma, and NSCLC. The authors demonstrated a
37% reduction of the risk of death in favor of immune checkpoint
inhibitors compared with control arm (175).
Recently, it has been demonstrated that the efficacy of the
treatment with immune checkpoint inhibitors can be influenced
by the composition of the host gut microbiota (176). As discussed
above, the gut microbiota influences the immune system of the
host. In fact, the interaction between specific microorganisms
molecular pathways and immune cells can regulate local or
systemic inflammation, hence influencing immune response
(177). In particular, in cancer patients, the gut microbiota
dysbiosis, caused by broad-spectrum antibiotic use, can be a
contributor to immune checkpoint inhibitors resistance. In one
study of 249 patients with NSCLC, renal cell carcinoma, and
urothelial carcinoma treated with MoAbs against PD-1/PD-L1, a
shotgun sequencing identified an overrepresentation of bacterial
genera including Akkermansia muciniphila in responders to
PD-1 inhibition compared with non-responders. In these
patients, lymphocyte reactivity against A. muciniphila and IFN-
γ production was significantly associated with survival (178).
The analysis of 112 buccal and fecal samples from patients with
metastatic melanoma also showed that the response to anti-PD-1
therapy depends on differences in the diversity and composition
of the patient gut microbiota of responders vs. non-responders
(179). These data demonstrated that, in responding patients,
there was a relative abundance of bacteria of theRuminococcaceae
family. Moreover, in mice and patients, T cell responses specific
for Bacteroides species, such as thetaiotaomicron or fragilis were
associated with the efficacy of CTLA-4 blockade. On the contrary,
tumors in antibiotic-treated or germ-free mice did not respond to
CTLA blockade (180). Moreover, fecal microbiota composition
of 26 patients with metastatic melanoma, using 16S rRNA, at
time 0 and before each Ipilimumab treatment, was clustered
on microbiota patterns. Baseline gut microbiota enriched with
Faecalibacterium and other Firmicutes was associated with
beneficial clinical response to Ipilimumab (181).
With the advent of immune checkpoint inhibitors
immunomodulation is going to revolutionize the clinical
management of at least some forms of cancer in older patients. In
spite of several controversial points, some clinical trials suggest
a significant benefit of immunotherapy in older patients, with
the exception of patients ≥75 years that obtain less benefit
from these treatments. Concerning this point, Metcalf et al.
(25) have demonstrated that CD28− costimulation is required
for the expansion of PD-1+ CD8T cells and effectiveness of
PD-1 therapy in murine models of chronic viral infection and
cancer. In addition, in lung cancer patients, PD-1+ CD8T cells
that proliferate in the peripheral blood after PD-1 blockade
express CD28. Therefore, these data, which imply selective
proliferation of CD28+ cells by PD-1 therapy, highlight one
mechanistic explanation why cancer patients older than 75 years
may not respond as well to immunotherapy as younger patients.
Understanding immune-regulatory functions is critical to
implement integrative immunomodulatory strategies targeting
checkpoints inhibitors.
Further studies of these checkpoints inhibitor functions might
provide to be of great therapeutic value also in improving T
cell responses to boost anti-microbial immunity and vaccine
efficacy during aging as well. The combination of immunological,
biochemical and systems biology data provides significant
support for using PD-1 as an important target for therapeutic
interventions of this type. In fact, studies carried out on HIV,
hepatitis B and hepatitis C infections have shown that blocking
the interaction PD-1/PD-L1 has a positive effect on the effector
functions of T cells. Furthermore, future studies focusing on the
elucidation of additive effects of blocking PD-1, other negative
regulatory molecules, and immunosuppressive cytokines will
help to identify combinatorial approaches that can improve T
effector responses to vaccination and therapeutic interventions
in older patients (182).
MAPK Pathway; Focus on p38 Regulation
Recently, the role of MAPKs pathways in the functional
competence of the immune system has been demonstrated
(183). The MAPK signaling pathways have been extensively
studied in the context of oncogenic function and proliferative
stimulus. However, these complex systems also regulate several
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functions of the innate and acquired immunity. They are also
involved in the production of pro-inflammatory cytokines, as
well as in the intracellular signaling cascades initiated when a
cytokine binds to its corresponding receptor (183). Three main
subgroups of MAPKs are known: Erk, Jnk, and p38. These
kinases can be targeted by small molecular weight compounds,
which act to inhibit the phosphorylation of proteins, hence
preventing their activation. Each one is separately regulated
within individual cells (184) [for an overview of kinase inhibitors
see (183)]. Understanding the immune-regulatory functions
exerted by MAPK pathways is critical to implement integrative
immunomodulatory strategies targeting these kinases.
The p38-MAPK pathway plays a pleiotropic role in cell
survival, both sustaining proliferation, and inducing apoptosis in
a cell type-specific manner, depending on the type of stimulus
(185). The p38-MAPK pathway stimulates the positive regulation
of Th1 differentiation and polarization. This pathway is not active
in Th2 cells (186). The p38-MAPK pathway is critical for the
production of inflammatory cytokines, positively regulating the
production of IFN-γ in CD4 and CD8 cells (187, 188).
The studies discussed below have been performed ex vivo in
mononuclear cells from mice and humans. They point out the
possibility to affect the second hallmark of immunosenescence
(the accumulation of memory T cells) through the regulation
of p38 activation. p38 is generally absent in senescent human
T cells. However, IFN-α signal can activate p38, triggering
cellular senescence, and leading to inhibition of proliferation
and telomerase activity in non-senescent T cells (189). It is
also associated with alterations of energetic metabolism as well
as autophagy. Autophagy, by inhibiting cell senescence, is a
critical regulator of memory CD8+ formation, and age-related
autophagy defect is one of the explanations why CD8+ Tmemory
formation becomes defective in old age (38, 185). In 2009,
Eisenberg et al. identified the use of spermidine, a polyamine
compound, to promote longevity, via autophagy, using PBMCs
as model. The authors monitored the survival cells using annexin
V/7-AAD as co-staining. After 12 days, 50% of the cells survived
after addition of spermidine. The rescuing effect did not involve
inhibition of apoptosis, as the percentage of apoptotic cells was
not influenced by spermidine. In fact, cell death, associated
with membrane rupture, was indicative of necrosis (190). In
immunosenescence models, CD8+ T cell can be also rejuvenated
in an autophagy dependent manner, using spermidine (191,
192). Low doses of a synthetic compound of natural spermidine
significantly suppressed autophagy in human Jurkat T cell line.
Moreover, the use of spermidine dramatically improved the
CD8+ T cell response to vaccination and infection in agedmice in
an autophagy-dependent manner, contributing to the increased
numbers of antigen-specific CD8+ T cells (191).
Moreover, the effector memory CD8+ T cells that express
CD45RA, are not functionally exhausted. Indeed, they preserve
the ability to secrete high levels of specific cytokines, such as
IFN-γ and TNF-α. Furthermore, they only express low levels
of key markers of exhaustion, such as PD-1. In these cells
that present characteristics of immune senescence (decreased
proliferation, lower telomerase activity, and increased presence
of DNA damage), the simultaneous blockade of both p38-MAPK
and PD-1 signaling supports their proliferation, both in young
and in older human beings. Secretion of TNF-α in some
populations of cells is reduced because of the contemporary arrest
of p38-MAPK and PD-1 pathways. However, the telomerase
activity in CD8+/CD45RA+ T cells is improved by blocking
only the p38 pathway but not the PD-1 signaling, indicating that
non-overlapping signaling pathways are involved (193, 194).
In addition to the inflammatory pathways that activate p38
through MAPK cascade by auto-phosphorylation, p38 can be
associated with AMPK complex in response to chronic antigenic
stimulation (see below, next paragraph).
The success of the studies using MAPK inhibitors, and kinase
inhibitors in general, allows the possibility to analyze, and
discover, the potential of these molecules in the treatment of
immunosenescence, targeting the second hallmark. For example,
a block at the level of p38-MAPK by sestrins causes age-related
signaling defects in effector and memory CD45RA+/CCR7−
T cells (195, 196). Sestrins, the mammalian products of the
Sesn1, Sesn2, and Sesn3 genes, are a family of stress sensing
proteins (196). Lanna et al. proposed a possible role for sestrins
in the control of the immune response, although this role
has not yet been fully determined. Sestrins exhibit pro-aging
activities in T senescent lymphocytes. The authors identified a
complex named sestrin-dependent MAPK activation complex
(sMAC) that simultaneously coordinates the activation of each
MAPK that controls a functional response. The knockout of
sMAC restored T cell activity (antigen-specific proliferation
and cytokine production) from older humans, and enhanced
responsiveness to influenza vaccination in the aged mice (196).
Examples of Nutrient Signaling Pathways:
AMPK and mTOR
The mechanisms exposed above are distinct from another
sestrin-inhibitory complex, containing GATOR and RAG A/B
GTPase that involves the mTOR pathway (197–199). In
particular, sestrins stimulate the activation of AMPK (by an
unknown mechanism), inhibiting mTORC1 signaling. This
suggests that the anti/pro-aging dichotomy of sestrin action in T
cells vs. other cell types may depend on different sestrin-protein
interactions (200).
In turn, senescent human CD27−/CD28−/CD4+ T cells
trigger AMPK to stimulate p38 recruitment, causing p38 auto-
phosphorylation mediated by the protein scaffold TAB1. This
pathway can inhibit telomerase activity, T cell proliferation,
and expression of key components of the TCR signalosome.
In the presence of low-nutrient levels and DNA-damage
signaling the proliferative defect of senescent T cells is
reversed by blocking AMPK-TAB1-dependent p38 activation
(38). Moreover, in senescent CD8+ T cells, p38-MAPK induces
an increase in autophagy through interactions between a p38
interacting protein and autophagy protein 9, in a mTOR-
independent manner, suggesting that p38-MAPK blockade
reverses senescence via mTOR-independent pathway (185).
mTOR plays an important role in T cell activation and
differentiation, especially of naïve CD4+ T cells in their
differentiation toward Th1 or Th17 phenotypes (201, 202). The
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activation of mTOR signaling pathway is under the control of
TCR/CD28 stimulation (201, 203). A growing body of research
has highlightedmTOR inhibitors, i.e., rapamycin and everolimus,
as promising treatments for several age-related pathologies,
including immunosenescence, prolonging lifespan, especially in
all four major animal models of aging: yeast, worms, flies,
and mice (204, 205). The partial inhibition of mTOR could
be beneficial for immune function in older people, although
mTOR activity inhibits autophagy. At high doses, rapamycin
is immunosuppressive, blocking both protein synthesis and cell
division. In a clinical trial of over 200 older participants, they
were assigned to a protocol including the use of mTOR complex
1 inhibitor everolimus, in different daily doses, for a 6-weeks
period. Participants, after a 2-weeks drug-free interval, were
challenged with the seasonal influenza vaccine. The two low-
dose everolimus regimens improved immune function without
causing serious side effects. Patients ameliorated their immune
response, with improved hematopoietic stem cell function
and a decreased proportion of PD-1+ lymphocytes (206).
In a subsequent follow-up study, combined BEZ235 (a dual
ATP-competitive PI3K and mTOR inhibitor) and everolimus
treatment for 6 weeks resulted in better infection control
in older adults for a year after treatment had ended (207).
However, rapamycin and Torin, another mTOR inhibitor, are
also reported to suppress the anti-inflammatory effects of
circulating glucocorticoids (208). These findings conflict with
earlier studies showing the central importance of mTOR in innate
immunity, specifically in the production of anti-inflammatory IL-
10 and the suppression of pro-inflammatory cytokines IL-21 and
IL-1β (209). The improved response after rapamycin treatment,
whichmight involve a decrease in the percentage of PD-1 positive
T cells, requires more detailed studies (207).
Data suggesting that nutrient signaling pathways may
negatively influence lymphocyte function in aging indicate the
possibility that inhibition of these pathways may enhance the
activity of lymphocytes from older adults (210). Broad ranges of
pharmacological agents with anti-immunosenescence properties
have been identified and other trials with agents, such as
rapamycin analogs are underway. Therefore, this represents a
promising therapeutic approach to improving the health of
older adults.
See Figure 2 for the main clinical approaches in
immunomodulatory interventions.
OTHER APPROACHES IN DEVELOPMENT
Other approaches focus on development of novel vaccines
especially suited to raise protective immunity in older adults by
overcoming the decrease in naïve cells. This approach includes
high-dose vaccines, booster vaccinations, different immunization
routes, and use of new adjuvant. The most used adjuvants
are based on aluminum salts. These adjuvants induce the
activation of APCs and strengthen the antigen immunogenicity
by their slower release and higher persistence at the vaccination
site. Another interesting compound is MF59, a squalene-based
adjuvant, which increases the chemokine-dependent recruitment
of APCs (211). However, adjuvants have shown only modest
success (212). Themost effective is generally considered complete
Freund adjuvant, which can only be used in animals because it
can cause a damaging skin inflammation (213). Therefore, there
is an unmet need for new vaccine strategies for older people.
The development an identification of appropriate adjuvants
and cytokines might effectively remedy defects in T cell functions
from older adults, both directly and by better activation of
DCs (214–216). Stimulation of TLRs by agonists seems to be
a promising strategy to enhance vaccine efficacy, because TLR
triggering can induce the production of cytokines by APCs,
and can promote germinal center antibody production (217,
218). Age-related variations in cytokine production are seen
in the APC isolated from older donors and efficient TLR
stimulation may overcome the age associated TLR signaling
dysfunction (219).
Triggering of multiple TLRs, using a combined adjuvant
for synergistic activation of cellular immunity (CASAC), is
an intriguing strategy. CASAC incorporates CpG (a single-
strand oligodeoxynucleotide, characterized by motifs containing
cytosines and guanines), which is a potent inducer of IFN-α
by pDCs, in combination with polyI:C (a synthetic analog of
viral dsRNA that targets TLR3, inducing the production of type
I IFNs). CASAC also contains IFN-γ and MHC-class I and II
peptides. This formulation results in potent cytotoxic T cell-
mediated immunity in young mice. In fact, immunization with
two ormore TLR agonists, an activator anti-CD40 antibody, IFN-
γ, and surfactants were sufficient to drive unprecedented levels
of CD8 responses to peptides or protein antigens and highly
polarized Th1 CD4 responses. CASAC stimulation activates both
mDCs and pDCs with IL-12 secretion. This strategy is more
effective than existing adjuvants and provides a technological
platform for rapid vaccine development (213).
Accordingly, in aged mice, antigen specific CD8+ T cell
responses were stimulated after serial vaccinations with CASAC
and a class I epitope, deriving either from ovalbumin or the
melanoma-associated self-antigen, tyrosinase-related protein-2.
Pentamer analysis revealed that aged, CASAC-vaccinated,
animals had substantially higher levels of antigen specific CD8+
T cells compared withmice vaccinated with complete/incomplete
Freund adjuvant. Therefore, CASAC promoted significantly
better functional CD8+ T cell activity (220).
An approach able to overcome age-related defects in CD4T
cell responses in vivo comes from the ability of combined
TLR ligands to induce the activation of peripheral blood DCs
isolated from older healthy donors (29). Preliminary in vitro
screening experiments suggest that, from the various TLR
agonists tested, the condition that most effectively activates DCs
is the combination of TLR7/TLR8 with TLR4. This TLR agonist
combination induces significantly greater cytokine production
than that induced by each of the individual agonists. This
greater stimulation is probably due to the combined activation
of both MyD88 and TRIF-dependent signal transduction
pathways. Stimulation with the specific combination of TLR
agonists, the imidazoquinoline R848 that targets TLR-7 and the
monophosphoryl lipid A that targets TLR-4, induces significantly
higher cytokine secretion by mDCs and pDCs from older
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FIGURE 2 | Overview of the main strategies of immunomodulation. (A) In age-related diseases, in particular in some metastatic cancers, the use of the monoclonal
antibody (such as Nivolumab, a PD-1 inhibitor) alone or in combination with other antagonists (PD-L1 antibody, like Atezolizumab) shows positive results on T cell
activities in older adults. These cells became able to respond to the action of their inhibitory receptors with a recovery of cytotoxic activity. (B) In old models, with Lack
of activity of CD8+, it is possible to rejuvenate CD8+ T cell responses in an autophagy dependent manner, using the polyamine compound spermidine. Spermidine
induces autophagy and prolongs lifespan in model organisms. Moreover, in the CD8+/CD45RA+/CCR7− T cells, a block at the level of MAPK p38 by sestrins causes
age-related signaling defects. The knockout of sMAC restores T cell activity (antigen-specific proliferation and cytokine production) in older humans, and enhances
responsiveness to influenza vaccination in old mice. (C) GATOR and RAG A/B GTPase make a sestrin-inhibitory complex that involves the mTOR pathway. In particular,
sestrins stimulate the activation of AMPK (by an unknown mechanism), inhibiting mTORC1 signaling. In addition, mTOR inhibitors, i.e., rapamycin and everolimus, are
promising treatments for several age-related pathologies, including immunosenescence, prolonging lifespan. A soft inhibition of mTOR could be beneficial for immune
function in older adults, although mTOR activity inhibits autophagy, and involves a decrease in the percentage of PD-1 positive T cells. See the text for the acronyms.
adults. This has potentially important implications, because the
reduced production of cytokines by pDCs from older people,
caused by defects in TLR signaling pathways, is associated
with an ineffective antibody response to influenza vaccination
(221). These findings highlight the efficient effect of adjuvants
in the stimulation of cytokine production and point toward
the potential use of appropriately selected combination of TLR
agonists in future vaccination approaches for older adults to
overcome the CD4 inability to respond.
CONCLUSION AND FUTURE
APPROACHES
Until a few decades ago, a very small fraction of the population
would reach 80 years of age. Now, in the Western world, this is
a frequent event, with the average life expectancy for a newborn
to have risen to 80 years in most Western European countries
(1). However, the increase in lifespan does not coincide with
increase in healthspan. The link between aging and disease is in
part a reflection of the functional changes in the immune system
of older people. Different factors contribute to the development
of age-related immune dysfunction, but the epilog of an aged
immune system is an increased propensity toward a reduced
resistance to infection, poorer responses to vaccination, and
the development of age-related diseases. The analysis of the
contributing factors to this profound immune remodeling has
revealed a complex network of alterations that influence both
innate and acquired arms of the immune system. The diversity
of cells, molecules and pathways involved in this remodeling,
and their ability to influence each other, including the intra-
and inter-individual variability of the immune response, make it
hard to identify interventions that can be predicted to improve
or, at least, to maintain the immune function in older adults.
Within the past few years, numerous studies of the underlying
mechanisms of age-related immune decline have laid the
groundwork for the identification of targeted approaches; some
of these have been discussed above, focusing on interventions
able to target the hallmarks of immunosenescence. Possible other
future approaches are reported below.
Taking into account the role of HCMV in the decrease of
naïve T cells and increase of memory T cells, the reduction
of the latent/lytic viral load, by vaccination and/or antiviral
drugs, should be beneficial to diminish HCMV-associated
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immunosenescence. Concerning the HCMV vaccine, Plotkin has
published an extensive review. As pointed out by the author, as
a result of 40 years of work, there are many candidate HCMV
vaccines, including live recombinants, replication-defective
virus, DNA plasmids, soluble pentameric proteins, peptides,
virus-like particles and vectored envelope proteins. Therefore,
we know the antigens needed in a HCMV vaccine, and that
vaccination can be protective. To reach the goal of an effective
HCMV vaccine, now we need a concentrated effort to combine
the important antigens and to generate durable responses
that will protect for a significant period. Interestingly, Plotkin
emphasizes that aside from the two main targets for disease
prevention, i.e., congenital infection and post-transplant disease,
immunosenescence might be a target for vaccination mediated
intervention, as well (222). Letermovir is an antiviral agent that
inhibits HCMV replication by binding to components of the
terminase complex. In patients undergoing hematopoietic stem
cell transplantation, Letermovir daily prophylaxis is effective
in preventing clinically significant HCMV infection when used
through day 100 after transplantation, with onlymild toxic effects
and with lower all-cause mortality than placebo (223). However,
there is no suggestion yet for the use of antiviral therapy as a
strategy for prophylactic mitigation of immunosenescence.
Finally, possible future strategies to combat
immunosenescence are represented by cellular and genetic
therapies, including bone marrow transplantation and genetic
reprogramming. In particular, genetically reprogramming cells
into induced pluripotent stem cells can rejuvenate any cell type
through telomere elongation, overcoming hurdles of replicative
senescence (224).
SUMMARY
In the first part of the review we define immunosenescence
and its relevance for the health of older persons, particularly
in the context of acquired immunity. In the second part of
the review we focus on the possible treatments to mitigate
immunosenescence. First, we pay great attention to positive and
negative effects of nutrition on immunosenescence. Then, we
analyze the possible immunotherapeutic role of interleukin-7
as well as of checkpoint and mitogen-activated protein kinases
inhibitors. Finally, we discuss a possible immunotherapeutic
intervention to enhance the response of older adults to vaccines,
i.e., the use of toll like receptor agonists. Therefore, we
present a comprehensive review of several possible therapeutic
interventions to alleviate immunosenescence.
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